Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Profit After Tax (2021 - 2025)

Historic Profit After Tax for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $7.4 million.

  • Arcutis Biotherapeutics' Profit After Tax rose 11783.95% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 7733.19%. This contributed to the annual value of -$140.0 million for FY2024, which is 4657.85% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Profit After Tax stood at $7.4 million, which was up 11783.95% from -$15.9 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Profit After Tax peaked at $7.4 million during Q3 2025, and registered a low of -$107.7 million during Q3 2022.
  • For the 5-year period, Arcutis Biotherapeutics' Profit After Tax averaged around -$50.2 million, with its median value being -$52.3 million (2024).
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 8902.95% in 2022, then skyrocketed by 11783.95% in 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Profit After Tax (Quarter) stood at -$71.3 million in 2021, then dropped by 0.97% to -$72.0 million in 2022, then rose by 7.96% to -$66.3 million in 2023, then surged by 83.72% to -$10.8 million in 2024, then skyrocketed by 168.69% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, -$15.9 million for Q2 2025, and -$25.1 million during Q1 2025.